Cost–utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting

Progress of targeted therapy for HER-2 positive breast cancer

“…DS-8201a, a novel ADC consisting of a trastuzumab , an enzymatic peptide linker, and a novel DNA topoisomerase I inhibitor, delutecan, was approved by the US FDA in December 2019 for the treatment of unresectable or metastatic HER-2-positive breast cancer [35] . Based on the results of the DESTINY-BREAST03 study, the first comparison of DS-8201a with T-DM1 in patients with unresectable or metastatic HER-2-positive breast cancer treated with trastuzumab and paclitaxel ISSN 2616-5791 Vol.4, Issue 6: 77-83, DOI: 10.25236/AJMHS.2023.040612…”